According to previous literature statistics [12], uveitis induced by pembrolizumab has an average onset time of approximately 84 days, while uveitis induced by PD-L1 inhibitors has an average onset time of around 25 days, meaning uveitis induced by PD-1 inhibitors tends to have a longer onset time than that induced by PD-L1 inhibitors. The gene discussed is PDCD1; the disease is uveitis.